The path(way) less traveled.
In this issue of Blood, Mathewson et al characterized targeting a novel intracellular pathway with an agent known to induce potent antitumor effects but now also appears to potently suppress inflammatory responses by dendritic cells (DCs) and prevent graft-vs-host disease (GVHD). Identifying agents that can suppress GVHD yet not compromise graft-vs-tumor (GVT) effects remains a paramount goal in allogeneic hematopoietic stem cell transplantation (HSCT).